Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
161. |
ECCT/22/10/03 | ISSC A randomized, double-blind, placebo-controlled trial to assess the safety, pharmacokinetics, and efficacy of escalating doses of oral ivermectin in scabies infected children weighing 5 to less than 15 kilograms in Kenya |
Principal Investigator(s) 1. Eunice Akinyi Ouma Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
View |
162. |
ECCT/16/07/02 | A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events |
Principal Investigator(s) 1. Mark Loeb Site(s) in Kenya The Aga Khan University Hospital |
View |
163. |
ECCT/18/07/06 | Hestia 3 A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Prof Jessie Nyokabi Githanga 2. Videlis Nduba 3. Janet N Oyieko 4. Bernards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Chandaria Health Center Clinical Research Clinic (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county) 4. KEMRI Kombewa Clinical Research Centre (Nairobi City county) 5. Kondele Children\'s Hospital (Kisumu county) 6. Strathmore University Medical Centre (Nairobi City county) |
View |
164. |
ECCT/09/03/01 | REMoxTB A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol, isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis |
Principal Investigator(s) 1. Evans Inyangala Amukoye Site(s) in Kenya Kibera D.O Health Centre |
View |
165. |
ECCT/19/06/01 | EPI 003 A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa. |
Principal Investigator(s) 1. Walter Otieno Site(s) in Kenya 1. Ahero clinical triasl unit (Kisumu county) 2. KEMI CDC (Siaya county) |
View |